Donor desmopressin is associated with superior graft survival after kidney transplantation.

Background: A recent randomized trial showed that pretreatment of the brain-dead donor with low-dose dopamine improves immediate kidney graft function, by limiting injury from cold storage (ClinicalTrials.gov Identifier: NCT00115115). This study determines whether donor exposure to desmopressin (1-deamino-8-d-arginine-vasopressin [DDAVP]) before organ retrieval affects renal transplant outcome.

Effects of donor pre-treatment with dopamine on survival after heart transplantation: a cohort study of heart transplant recipients nested in a randomized controlled multicenter trial.

Objectives: We determined the outcome of cardiac allografts from multiorgan donors enrolled in a randomized trial of donor pre-treatment with dopamine.

Background: Treatment of the brain-dead donor with low-dose dopamine improves immediate graft function after kidney transplantation.

Methods: A cohort study of 93 heart transplants from 21 European centers was undertaken between March 2004 and August 2007.

Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial.

Context: Kidney graft function after transplantation can be improved through pharmacological donor pretreatment to limit organ injury from cold preservation.

Objective: To determine whether pretreatment of brain-dead donors with low-dose dopamine improves early graft function in human renal transplant recipients.

Design, Setting, And Patients: Randomized, open-label, multicenter, parallel-group trial of 264 deceased heart-beating donors and 487 subsequent renal transplants performed at 60 European centers between March 2004 and August 2007 (final follow-up, December 31, 2008).

Cost-benefit approach in evaluating investment into donor action: the German case.

Donor Action (DA) is an international initiative to help critical care units (CCUs) increase their own donation rates through improved-quality donation practices. Following a validated diagnostic review (DR), areas of weakness can be identified, and the appropriate changes introduced. Data gathered from a number of centers in nine European countries (including Germany) 1 year after the introduction of targeted improvement measures demonstrated a 59.